Guidelines for Transparency on Gut Microbiome Studies in Essential and Experimental Hypertension

Francine Z. Marques, Hamdi A. Jama, Kirill Tsyganov, Paul A. Gill, Dakota Rhys-Jones, Rikeish R. Muralitharan, Jane Muir, Andrew Holmes, Charles R. Mackay

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Hypertension is a complex and modifiable condition in which environmental factors contribute to both onset and progression. Recent evidence has accumulated for roles of diet and the gut microbiome as environmental factors in blood pressure regulation. However, this is complex because gut microbiomes are a unique feature of each individual reflecting that individual's developmental and environmental history creating caveats for both experimental models and human studies. Here, we describe guidelines for conducting gut microbiome studies in experimental and clinical hypertension. We provide a complete guide for authors on proper design, analyses, and reporting of gut microbiota/microbiome and metabolite studies and checklists that can be used by reviewers and editors to support robust reporting and interpretation. We discuss factors that modulate the gut microbiota in animal (eg, cohort, controls, diet, developmental age, housing, sex, and models used) and human studies (eg, blood pressure measurement and medication, body mass index, demographic characteristics including age, cultural identification, living structure, sex and socioeconomic environment, and exclusion criteria). We also provide best practice advice on sampling, storage of fecal/cecal samples, DNA extraction, sequencing methods (including metagenomics and 16S rRNA), and computational analyses. Finally, we discuss the measurement of short-chain fatty acids, metabolites produced by the gut microbiota, and interpretation of data. These guidelines should support better transparency, reproducibility, and translation of findings in the field of gut microbiota/microbiome in hypertension and cardiovascular disease.

Original languageEnglish
Pages (from-to)1279-1293
Number of pages15
JournalHypertension
Volume74
Issue number6
DOIs
Publication statusPublished - Dec 2019

Keywords

  • computational biology
  • gastrointestinal microbiome
  • metabolomics
  • metagenomics
  • microbiota

Cite this

Marques, Francine Z. ; Jama, Hamdi A. ; Tsyganov, Kirill ; Gill, Paul A. ; Rhys-Jones, Dakota ; Muralitharan, Rikeish R. ; Muir, Jane ; Holmes, Andrew ; Mackay, Charles R. / Guidelines for Transparency on Gut Microbiome Studies in Essential and Experimental Hypertension. In: Hypertension. 2019 ; Vol. 74, No. 6. pp. 1279-1293.
@article{be040edde7f24bb29df5325ff4f6fd17,
title = "Guidelines for Transparency on Gut Microbiome Studies in Essential and Experimental Hypertension",
abstract = "Hypertension is a complex and modifiable condition in which environmental factors contribute to both onset and progression. Recent evidence has accumulated for roles of diet and the gut microbiome as environmental factors in blood pressure regulation. However, this is complex because gut microbiomes are a unique feature of each individual reflecting that individual's developmental and environmental history creating caveats for both experimental models and human studies. Here, we describe guidelines for conducting gut microbiome studies in experimental and clinical hypertension. We provide a complete guide for authors on proper design, analyses, and reporting of gut microbiota/microbiome and metabolite studies and checklists that can be used by reviewers and editors to support robust reporting and interpretation. We discuss factors that modulate the gut microbiota in animal (eg, cohort, controls, diet, developmental age, housing, sex, and models used) and human studies (eg, blood pressure measurement and medication, body mass index, demographic characteristics including age, cultural identification, living structure, sex and socioeconomic environment, and exclusion criteria). We also provide best practice advice on sampling, storage of fecal/cecal samples, DNA extraction, sequencing methods (including metagenomics and 16S rRNA), and computational analyses. Finally, we discuss the measurement of short-chain fatty acids, metabolites produced by the gut microbiota, and interpretation of data. These guidelines should support better transparency, reproducibility, and translation of findings in the field of gut microbiota/microbiome in hypertension and cardiovascular disease.",
keywords = "computational biology, gastrointestinal microbiome, metabolomics, metagenomics, microbiota",
author = "Marques, {Francine Z.} and Jama, {Hamdi A.} and Kirill Tsyganov and Gill, {Paul A.} and Dakota Rhys-Jones and Muralitharan, {Rikeish R.} and Jane Muir and Andrew Holmes and Mackay, {Charles R.}",
year = "2019",
month = "12",
doi = "10.1161/HYPERTENSIONAHA.119.13079",
language = "English",
volume = "74",
pages = "1279--1293",
journal = "Hypertension",
issn = "0194-911X",
publisher = "American Heart Association",
number = "6",

}

Guidelines for Transparency on Gut Microbiome Studies in Essential and Experimental Hypertension. / Marques, Francine Z.; Jama, Hamdi A.; Tsyganov, Kirill; Gill, Paul A.; Rhys-Jones, Dakota; Muralitharan, Rikeish R.; Muir, Jane; Holmes, Andrew; Mackay, Charles R.

In: Hypertension, Vol. 74, No. 6, 12.2019, p. 1279-1293.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Guidelines for Transparency on Gut Microbiome Studies in Essential and Experimental Hypertension

AU - Marques, Francine Z.

AU - Jama, Hamdi A.

AU - Tsyganov, Kirill

AU - Gill, Paul A.

AU - Rhys-Jones, Dakota

AU - Muralitharan, Rikeish R.

AU - Muir, Jane

AU - Holmes, Andrew

AU - Mackay, Charles R.

PY - 2019/12

Y1 - 2019/12

N2 - Hypertension is a complex and modifiable condition in which environmental factors contribute to both onset and progression. Recent evidence has accumulated for roles of diet and the gut microbiome as environmental factors in blood pressure regulation. However, this is complex because gut microbiomes are a unique feature of each individual reflecting that individual's developmental and environmental history creating caveats for both experimental models and human studies. Here, we describe guidelines for conducting gut microbiome studies in experimental and clinical hypertension. We provide a complete guide for authors on proper design, analyses, and reporting of gut microbiota/microbiome and metabolite studies and checklists that can be used by reviewers and editors to support robust reporting and interpretation. We discuss factors that modulate the gut microbiota in animal (eg, cohort, controls, diet, developmental age, housing, sex, and models used) and human studies (eg, blood pressure measurement and medication, body mass index, demographic characteristics including age, cultural identification, living structure, sex and socioeconomic environment, and exclusion criteria). We also provide best practice advice on sampling, storage of fecal/cecal samples, DNA extraction, sequencing methods (including metagenomics and 16S rRNA), and computational analyses. Finally, we discuss the measurement of short-chain fatty acids, metabolites produced by the gut microbiota, and interpretation of data. These guidelines should support better transparency, reproducibility, and translation of findings in the field of gut microbiota/microbiome in hypertension and cardiovascular disease.

AB - Hypertension is a complex and modifiable condition in which environmental factors contribute to both onset and progression. Recent evidence has accumulated for roles of diet and the gut microbiome as environmental factors in blood pressure regulation. However, this is complex because gut microbiomes are a unique feature of each individual reflecting that individual's developmental and environmental history creating caveats for both experimental models and human studies. Here, we describe guidelines for conducting gut microbiome studies in experimental and clinical hypertension. We provide a complete guide for authors on proper design, analyses, and reporting of gut microbiota/microbiome and metabolite studies and checklists that can be used by reviewers and editors to support robust reporting and interpretation. We discuss factors that modulate the gut microbiota in animal (eg, cohort, controls, diet, developmental age, housing, sex, and models used) and human studies (eg, blood pressure measurement and medication, body mass index, demographic characteristics including age, cultural identification, living structure, sex and socioeconomic environment, and exclusion criteria). We also provide best practice advice on sampling, storage of fecal/cecal samples, DNA extraction, sequencing methods (including metagenomics and 16S rRNA), and computational analyses. Finally, we discuss the measurement of short-chain fatty acids, metabolites produced by the gut microbiota, and interpretation of data. These guidelines should support better transparency, reproducibility, and translation of findings in the field of gut microbiota/microbiome in hypertension and cardiovascular disease.

KW - computational biology

KW - gastrointestinal microbiome

KW - metabolomics

KW - metagenomics

KW - microbiota

UR - http://www.scopus.com/inward/record.url?scp=85074963458&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.119.13079

DO - 10.1161/HYPERTENSIONAHA.119.13079

M3 - Article

VL - 74

SP - 1279

EP - 1293

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 6

ER -